Shaun Claydon has been appointed as chief financial officer (CFO) and company secretary at Frontier IP with immediate effect.

He has joined the intellectual property group with over 20 years’ experience in senior financial leadership, including more than 15 years at board-level.

Claydon was previously CFO at Actimed Therapeutics, where he served he co-led a Series B equity funding round, securing a multi-million investment for clinical programmes.

Prior to this, Claydon served as CFO at Destiny Pharma between 2018 and 2024. He has also held roles at HSBC Investment Banking, BDO LLP, Evolution Securities and PwC.

Claydon has replaced Jo Stent, who announced on 6 November that she was to leave the company and the board. She will remain employed by the group for an additional short period to ensure an orderly handover of responsibilities.

Chief executive at Frontier IP, Neil Crabb, said: "I am delighted to welcome Shaun to our board of directors and to the wider group. Shaun brings significant expertise and experience, particularly in areas of key focus for our portfolio companies, including equity fundraising, IPOs and M&A. He will play a vital role in the next stage of our growth as we focus on developing our portfolio companies towards exit."

Claydon concluded: "I am very pleased to be joining Frontier IP at this important stage of its development. I look forward to helping the group and its portfolio companies realise their full potential. I look forward to working with Jo over the coming weeks to ensure a seamless handover of responsibilities."

---